Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 6,160 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 6,160 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $18.01, for a total value of $110,941.60. Following the completion of the sale, the insider owned 1,405,898 shares in the company, valued at approximately $25,320,222.98. This represents a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Price Performance

ADPT opened at $16.78 on Thursday. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $20.76. The stock has a market cap of $2.69 billion, a P/E ratio of -50.85 and a beta of 2.15. The stock’s 50 day moving average price is $14.72 and its 200 day moving average price is $15.59.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same period last year, the firm earned ($0.20) EPS. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Wall Street Analyst Weigh In

ADPT has been the topic of several research analyst reports. Guggenheim reiterated a “buy” rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Morgan Stanley lowered their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. JPMorgan Chase & Co. decreased their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.33.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Adaptive Biotechnologies and set a $22 price target, implying meaningful upside from recent trading levels.
• Positive Sentiment: The company priced an upsized $300 million offering of 0% convertible senior notes due 2031, and management said proceeds will help repay the OrbiMed agreement, fund capped-call protection, and support a $25 million share repurchase to reduce dilution.
• Neutral Sentiment: The initial conversion price of about $24.11 per share and capped-call structure may help limit dilution if the stock rises, which could support longer-term sentiment.
• Negative Sentiment: Investors may view the larger convertible issuance as a sign of financing needs, especially since the offering was increased from $250 million to $300 million.
• Negative Sentiment: Insider selling added pressure: Chief Scientific Officer Harlan S. Robins sold 106,160 shares in two recent transactions, and the company’s recent insider activity has consisted entirely of sales.
• Negative Sentiment: A prior report also noted the stock fell after the original convertible-debt plan, suggesting shareholders are sensitive to dilution and capital-structure changes.

Institutional Trading of Adaptive Biotechnologies

Hedge funds and other institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth $28,000. EverSource Wealth Advisors LLC boosted its position in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the period. Assetmark Inc. boosted its position in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth $51,000. Finally, Strive Financial Group LLC acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.